Welcome!

News Feed Item

Sickle Cell Disease Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Sickle Cell Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/689745/Sickle-Cell-Disease-Global-Clinical-Trials-Review-H2-2014.html

Sickle Cell Disease Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Sickle Cell Disease Global Clinical Trials Review, H2, 2014" provides data on the Sickle Cell Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sickle Cell Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sickle Cell Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Sickle Cell Disease 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Sickle Cell Disease 25
Subjects Recruited Over a Period of Time 30
Clinical Trials by Sponsor Type 31
Prominent Sponsors 32
Top Companies Participating in Sickle Cell Disease Therapeutics Clinical Trials 33
Prominent Drugs 35
Latest Clinical Trials News on Sickle Cell Disease 36
Jun 16, 2014: Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial 36
Clinical Trial Profiles 37
Clinical Trial Overview of Top Companies 37
Novartis AG 37
Clinical Trial Overview of Novartis AG 37
Eli Lilly and Company 38
Clinical Trial Overview of Eli Lilly and Company 38
Pfizer Inc. 39
Clinical Trial Overview of Pfizer Inc. 39
Prolong Pharmaceuticals 40
Clinical Trial Overview of Prolong Pharmaceuticals 40
HemaQuest Pharmaceuticals, Inc. 41
Clinical Trial Overview of HemaQuest Pharmaceuticals, Inc. 41
Selexys Pharmaceuticals Corporation 42
Clinical Trial Overview of Selexys Pharmaceuticals Corporation 42
Ikaria Inc. 43
Clinical Trial Overview of Ikaria Inc. 43
Emmaus Life Sciences, Inc. 44
Clinical Trial Overview of Emmaus Life Sciences, Inc. 44
Baxter International Inc. 45
Clinical Trial Overview of Baxter International Inc. 45
Clinical Trial Overview of Top Institutes / Government 46
National Heart, Lung, and Blood Institute 46
Clinical Trial Overview of National Heart, Lung, and Blood Institute 46
Assistance Publique - Hopitaux de Paris 49
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 49
HaEmek Medical Center 50
Clinical Trial Overview of HaEmek Medical Center 50
Cincinnati Children's Hospital Medical Center 51
Clinical Trial Overview of Cincinnati Children's Hospital Medical Center 51
Duke University 52
Clinical Trial Overview of Duke University 52
Emory University 53
Clinical Trial Overview of Emory University 53
National Institutes of Health Clinical Center 54
Clinical Trial Overview of National Institutes of Health Clinical Center 54
Baylor College of Medicine 55
Clinical Trial Overview of Baylor College of Medicine 55
Children's Hospital & Research Center Oakland 56
Clinical Trial Overview of Children's Hospital & Research Center Oakland 56
Five Key Clinical Profiles 57
Appendix 99
Abbreviations 99
Definitions 99
Research Methodology 100
Secondary Research 101
About GlobalData 101
Contact Us 101
Disclaimer 101
Source 102

List of Tables
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Region, 2014* 7
Sickle Cell Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Sickle Cell Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Sickle Cell Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Sickle Cell Disease Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Sickle Cell Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Sickle Cell Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, G7 Countries (%), 2014* 15
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, E7 Countries (%), 2014* 18
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Sickle Cell Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Sickle Cell Disease Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Sickle Cell Disease Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Sickle Cell Disease Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Sickle Cell Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 30
Sickle Cell Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 31
Sickle Cell Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 32
Sickle Cell Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Sickle Cell Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 35
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 37
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 38
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 39
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Prolong Pharmaceuticals, 2014* 40
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by HemaQuest Pharmaceuticals, Inc., 2014* 41
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Selexys Pharmaceuticals Corporation, 2014* 42
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Ikaria Inc., 2014* 43
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Emmaus Life Sciences, Inc., 2014* 44
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Baxter International Inc., 2014* 45
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 46
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 49
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by HaEmek Medical Center, 2014* 50
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Cincinnati Children's Hospital Medical Center, 2014* 51
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 52
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2014* 53
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institutes of Health Clinical Center, 2014* 54
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Baylor College of Medicine, 2014* 55
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Hospital & Research Center Oakland, 2014* 56

List of Figures
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Sickle Cell Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Sickle Cell Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Sickle Cell Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Sickle Cell Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Sickle Cell Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Sickle Cell Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, G7 Countries (%), 2014* 15
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, E7 Countries (%), 2014* 18
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Sickle Cell Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Sickle Cell Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 30
Sickle Cell Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 31
Sickle Cell Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 32
Sickle Cell Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 33
Sickle Cell Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 35
GlobalData Methodology 100

Read the full report:
Sickle Cell Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/689745/Sickle-Cell-Disease-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and ...
For better or worse, DevOps has gone mainstream. All doubt was removed when IBM and HP threw up their respective DevOps microsites. Where are we on the hype cycle? It's hard to say for sure but there's a feeling we're heading for the "Peak of Inflated Expectations." What does this mean for the enterprise? Should they avoid DevOps? Definitely not. Should they be cautious though? Absolutely. The truth is that DevOps and the enterprise are at best strange bedfellows. The movement has its roots in t...
DXWorldEXPO LLC, the producer of the world's most influential technology conferences and trade shows has announced the 22nd International CloudEXPO | DXWorldEXPO "Early Bird Registration" is now open. Register for Full Conference "Gold Pass" ▸ Here (Expo Hall ▸ Here)
Vulnerability management is vital for large companies that need to secure containers across thousands of hosts, but many struggle to understand how exposed they are when they discover a new high security vulnerability. In his session at 21st Cloud Expo, John Morello, CTO of Twistlock, addressed this pressing concern by introducing the concept of the “Vulnerability Risk Tree API,” which brings all the data together in a simple REST endpoint, allowing companies to easily grasp the severity of the ...
"We are a well-established player in the application life cycle management market and we also have a very strong version control product," stated Flint Brenton, CEO of CollabNet,, in this SYS-CON.tv interview at 18th Cloud Expo at the Javits Center in New York City, NY.
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., discussed how these tools can be leveraged to develop a lasting competitive advantage ...
In his session at @ThingsExpo, Arvind Radhakrishnen discussed how IoT offers new business models in banking and financial services organizations with the capability to revolutionize products, payments, channels, business processes and asset management built on strong architectural foundation. The following topics were covered: How IoT stands to impact various business parameters including customer experience, cost and risk management within BFS organizations.
In his session at 20th Cloud Expo, Scott Davis, CTO of Embotics, discussed how automation can provide the dynamic management required to cost-effectively deliver microservices and container solutions at scale. He also discussed how flexible automation is the key to effectively bridging and seamlessly coordinating both IT and developer needs for component orchestration across disparate clouds – an increasingly important requirement at today’s multi-cloud enterprise.
Here are the Top 20 Twitter Influencers of the month as determined by the Kcore algorithm, in a range of current topics of interest from #IoT to #DeepLearning. To run a real-time search of a given term in our website and see the current top influencers, click on the topic name. Among the top 20 IoT influencers, ThingsEXPO ranked #14 and CloudEXPO ranked #17.
While the focus and objectives of IoT initiatives are many and diverse, they all share a few common attributes, and one of those is the network. Commonly, that network includes the Internet, over which there isn't any real control for performance and availability. Or is there? The current state of the art for Big Data analytics, as applied to network telemetry, offers new opportunities for improving and assuring operational integrity. In his session at @ThingsExpo, Jim Frey, Vice President of S...
Given the popularity of the containers, further investment in the telco/cable industry is needed to transition existing VM-based solutions to containerized cloud native deployments. The networking architecture of the solution isolates the network traffic into different network planes (e.g., management, control, and media). This naturally makes support for multiple interfaces in container orchestration engines an indispensable requirement.
Your homes and cars can be automated and self-serviced. Why can't your storage? From simply asking questions to analyze and troubleshoot your infrastructure, to provisioning storage with snapshots, recovery and replication, your wildest sci-fi dream has come true. In his session at @DevOpsSummit at 20th Cloud Expo, Dan Florea, Director of Product Management at Tintri, provided a ChatOps demo where you can talk to your storage and manage it from anywhere, through Slack and similar services with...
Containers are rapidly finding their way into enterprise data centers, but change is difficult. How do enterprises transform their architecture with technologies like containers without losing the reliable components of their current solutions? In his session at @DevOpsSummit at 21st Cloud Expo, Tony Campbell, Director, Educational Services at CoreOS, will explore the challenges organizations are facing today as they move to containers and go over how Kubernetes applications can deploy with lega...
In their session at @DevOpsSummit at 21st Cloud Expo, Michael Berman, VP Engineering at TidalScale, and Ivo Jimenez, Engineer at TidalScale, will describe how automating tests in TidalScale is easy thanks to WaveRunner. They will show how they use WaveRunner, Jenkins, and Docker to have agile delivery of TidalScale. Michael Berman is VP Engineering at TidalScale. TidalScale is developing a scale up compute and resource architecture for customers to perform big data exploration and real time anal...
With the introduction of IoT and Smart Living in every aspect of our lives, one question has become relevant: What are the security implications? To answer this, first we have to look and explore the security models of the technologies that IoT is founded upon. In his session at @ThingsExpo, Nevi Kaja, a Research Engineer at Ford Motor Company, discussed some of the security challenges of the IoT infrastructure and related how these aspects impact Smart Living. The material was delivered interac...